RankAlpha logo
Back to Rankings

RCUS

Arcus BiosciencesC
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
View Chart
Current thesis
The best post-print argument is that May 5 clarified the story rather than damaging it further: cash runway extends into at least H2 2028, near-term spend should ease as domvanalimab winds down, and management laid out a concentrated sequence of 2026-2027 RCC milestones around casdatifan plus a secondary quemliclustat option. [#8-K-2026-05-05]
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.2.
What can break
After STAR-121 was stopped for futility, Arcus disclosed that the domvanalimab-based combination did not improve overall survival versus pembrolizumab plus chemotherapy, raising the risk that the company has materially less late-stage diversification than it had earlier in 2026. [#8-K-2026-05-05]
Momentum
78
Value
41
Sentiment
40
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $28.00 · Bull $36.00 · Bear $17.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $37.91
Why
Momentum78 · Δ7d -1.2
Value41 · Δ7d +0.0
Sentiment40 · Δ7d +1.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
78
26% active weight
Current posture
7d trendFlat
Δ7d
-1.2
Δ21d
-8.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
40
34% active weight
Current posture
7d trendImproving
Δ7d
+1.9
Δ21d
+9.4
Why this grade

Composite grade C. Momentum 77.6 / Value 41.1 / Sentiment 39.6

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$3.44B
Beta
0.85
Shares Out
125.77M
P/E (TTM) · Derived
-8.3
P/S (TTM)
11.14
P/FCF (TTM) · Derived
-6.39
Rev YoY
-39.3%
EPS YoY
-10.3%
Gross Margin
+96.2%
Op Margin
-156.3%
Net Debt
-$783M
Current Ratio
4.04
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology